Novartis AG (NVS)

86.97
0.41 0.47
NYSE : Health Technology
Prev Close 86.56
Open 85.93
Day Low/High 85.92 / 87.38
52 Wk Low/High 74.97 / 96.31
Volume 4.07M
Avg Volume 1.82M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 219.04B
EPS 5.50
P/E Ratio 16.15
Div & Yield 1.84 (2.11%)
Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round

Blackberry, SkyWest, Apache: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Blackberry, SkyWest, Apache, Philip Morris International, PetMed Express, Iron Mountain, Novartis.

Behind the Selloff: Cramer's 'Mad Money' Recap (Friday 4/6/18)

Behind the Selloff: Cramer's 'Mad Money' Recap (Friday 4/6/18)

This market is deceptive and you need to recognize your sense of timing is not infallible. So, adjust your scales and get ready for next week, says Jim Cramer.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

If Stocks Don't Pop on All This Deals News Investors Better Look Out Below

M&A activity kicks into high gear going into the final days of the first quarter. If the broader stock market doesn't pop on this news, it would be a red flag.

The Dow Plunges Into the Close of Trading on Tuesday

The Dow Plunges Into the Close of Trading on Tuesday

Cooling tensions with China aren't enough to save investors on Tuesday.

Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday

Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday

With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.

Facebook, Novartis, GSK, Uber and Deutsche Bank - 5 Things You Must Know

Facebook, Novartis, GSK, Uber and Deutsche Bank - 5 Things You Must Know

U.S. stock futures rise and global stocks extend their rally; Novartis to sell 36.5% stake in joint venture to partner GSK for $13 billion; Facebook's Mark Zuckerberg won't face U.K. lawmakers.

Global Stocks Ride Wall Street Wave as U.S.-China Trade Talks Tempt Bulls

Global Stocks Ride Wall Street Wave as U.S.-China Trade Talks Tempt Bulls

Wall Street's best day in nearly three years has global stocks on the move Tuesday, with U.S.-China trade talks and a wave of late quarter M&A boosting markets around the world.

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Here's what you need to know now for Tuesday, March 6.

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.

Dow, S&P 500 and Nasdaq Finish Higher, Posting Third Consecutive Day of Gains

Dow, S&P 500 and Nasdaq Finish Higher, Posting Third Consecutive Day of Gains

Stocks ended higher on Tuesday.

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

There Is Good and a Lot of Bad in General Electric Earnings

There Is Good and a Lot of Bad in General Electric Earnings

John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

The FDA approved 11 different hematological treatments this year after approving 11 in the previous two years combined.

3 Things You Must Know About Wall Street as You Head to Lunch

3 Things You Must Know About Wall Street as You Head to Lunch

The Dow Jones Industrial Average soars on Monday, and the S&P 500 posts a sharp increase as the Senate passes its version of U.S. tax reform.

What Does CVS's Aetna Acquisition Mean for Amazon?

What Does CVS's Aetna Acquisition Mean for Amazon?

Is CVS's planned acquisition of Aetna just a reaction to Amazon's dive into healthcare? Here's what we know so far.

CVS Spends $69 Billion to Buy Aetna -- All Eyes Now on Amazon

CVS Spends $69 Billion to Buy Aetna -- All Eyes Now on Amazon

Insiders are already looking beyond the upcoming merger to the patron saint of disruption Amazon.

Amazon's Move Into Retail Pharmacy Could Put 10% of Industry Profits at Risk

Amazon's Move Into Retail Pharmacy Could Put 10% of Industry Profits at Risk

The likes of CVS and Walgreens could suffer if Amazon follows through on reported talks it's held with Mylan and Sandoz to get its feet wet in the prescription drug retail market.

Senate Tax Bill, Car Sales and Amazon - 5 Things You Must Know

Senate Tax Bill, Car Sales and Amazon - 5 Things You Must Know

U.S. stock futures are pointing to losses for Wall Street on Friday, after the Senate delays a vote on its tax reform bill over deficit concerns.

Novartis Reportedly Taps Centerview to Evaluate Options for Dermatology Business

Novartis Reportedly Taps Centerview to Evaluate Options for Dermatology Business

The Switzerland-headquartered drug manufacturer is reportedly mulling a sale of its dermatology generics drug unit, which is based primarily in the U.S.

GlaxoSmithKline Wins FDA Approval to Develop 'Breakthrough' Blood Cancer Drug

GlaxoSmithKline Wins FDA Approval to Develop 'Breakthrough' Blood Cancer Drug

The FDA cleared GSK's new drug for fast-track development with quicker regulatory review.

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.

Starbucks Might Be About to Shock the Hell Out of Wall Street

Starbucks Might Be About to Shock the Hell Out of Wall Street

Starbucks used to be a can't miss investment. But this year the stock has languished for a variety of reasons. Wall Street could get a scary wake-up call.

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.

TheStreet Quant Rating: A- (Buy)